Teratogenicity and neonatal toxicity of ifosfamide in mice.
D000014:Abnormalities, Drug-Induced; D000477:Alkylating Agents / Q000008:administration & dosage / Q000378:metabolism / Q000494:pharmacology* / Q000633:toxicity; D000818:Animals; D000831:Animals, Newborn; D001835:Body Weight / Q000187:drug effects; D001842:Bone and Bones / Q000002:abnormalities / Q000187:drug effects; D003498:Cyclic P-Oxides / Q000378:metabolism / Q000494:pharmacology* / Q000633:toxicity; D003520:Cyclophosphamide / Q000494:pharmacology; D005021:Ethylamines / Q000494:pharmacology; D005260:Female; D005333:Fetus / Q000187:drug effects*; D005865:Gestational Age; D006849:Hydrocephalus / Q000139:chemically induced; D006869:Hydronephrosis / Q000139:chemically induced; D007668:Kidney / Q000002:abnormalities; D008297:Male; D008431:Maternal-Fetal Exchange; D051379:Mice; D010078:Oxazines / Q000378:metabolism / Q000494:pharmacology* / Q000633:toxicity; D011247:Pregnancy
D000477:Alkylating Agents; D003498:Cyclic P-Oxides; D005021:Ethylamines; D010078:Oxazines; D003520:Cyclophosphamide